607373-89-7

Basic information

• Product Name: (2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE
• Synonyms: (2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE;2-chloro-N-ethyl-5-nitropyridin-4-amine
• CAS NO: 607373-89-7
• Molecular Formula: C₇H₈ClN₃O₂
• Molecular Weight: 201.61
• Mol File: 607373-89-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 350.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.415±0.06 g/cm3(Predicted)
• PKA: -1.29±0.10(Predicted)
• CAS DataBase Reference: (2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE(607373-89-7)
• EPA Substance Registry System: (2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE(607373-89-7)

Safety Data

• Hazardous Substances Data: 607373-89-7(Hazardous Substances Data)

Usage

Description

(2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE is a chemical compound characterized by a pyridine ring with a chlorine atom at the 2-position and a nitro group at the 5-position. It features an ethylamine group attached to the 4-position of the pyridine ring, which contributes to its unique structure and reactivity.

Uses

Used in Organic Synthesis:
(2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE is used as a building block in organic synthesis for the creation of various pharmaceuticals, agrochemicals, and other biologically active molecules. Its distinctive structure and reactivity make it a valuable intermediate for producing a wide range of compounds.
Used in Chemical Research:
In the field of chemical research, (2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE serves as an important intermediate for the development of new compounds with potential therapeutic and agricultural applications. Its unique properties allow researchers to explore its potential in creating novel molecules for various uses.
Used in Pharmaceutical Industry:
(2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE is used as a key intermediate in the pharmaceutical industry for the synthesis of drugs with potential therapeutic effects. Its unique structure allows for the development of new medications that can address unmet medical needs.
Used in Agrochemical Industry:
In the agrochemical industry, (2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE is utilized as a precursor for the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and structural features enable the creation of effective compounds for agricultural applications.
Safety Note:
It is crucial to handle (2-CHLORO-5-NITRO-PYRIDIN-4-YL)-ETHYL-AMINE with care, as it may pose hazards if not properly managed. Proper safety measures should be taken during its synthesis, storage, and use to ensure the well-being of individuals and the environment.

Upstream product

• 607373-83-1 2-chloro-4-methoxy-5-nitro-pyridine 
• 75-04-7 ethylamine 
• 5435-54-1 4-hydroxy-3-nitropyridine 

Downstream Products

• 925213-66-7 N-(3-{[4-(ethylamino)-5-nitro-2-pyridinyl]oxy}phenyl)-4-methylbenzenesulfonamide 
• 850664-28-7 N-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-{[2-(4-morpholinyl)ethyl]oxy}-3-pyridinecarboxamide 
• 850663-69-3 N-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide 
• 850663-71-7 N-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-pyridinecarboxamide 
• 850663-68-2 1,1-dimethylethyl (3-{[5-amino-4-(ethylamino)-2-pyridinyl]oxy}phenyl)carbamate 
• 913642-20-3 1,1-dimethylethyl [2-({3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]phenyl}amino)-2-oxoethyl]carbamate 
• 913640-04-7 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol 
• 1025507-77-0 (R)-4-cyano-N-(1-(1-ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)ethyl)benzenesulfonamide 
• 1449665-27-3 1-ethyl-N-(2-ethylphenyl)-N-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449669-36-6 (1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl)-(2-ethylphenyl)amine 
• 1357158-67-8 1-(4-(1-ethyl-7-phenyl-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)cyclobutanamine 
• 1357159-17-1 tert-butyl 1-(4-(5-amino-4-(ethylamino)-3-phenylpyridin-2-yl)phenyl)cyclobutylcarbamate 
• 1357159-16-0 tert-butyl 1-(4-(4-(ethylamino)-5-nitro-3-phenylpyridin-2-yl)phenyl)cyclobutylcarbamate 
• 1357159-15-9 tert-butyl 1-(4-(3-chloro-4-(ethylamino)-5-nitropyridin-2-yl)phenyl)cyclobutylcarbamate 

Relevant articles and documents

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

Discovery of aminofurazan-azabenzimidazoles as inhibitors of rho-kinase with high kinase selectivity and antihypertensive activity

The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension. Despite many available treatments, hypertension remains a prevalent problem. In fact, some 30% of hypertensive patients are unable to reach their blood pressure goals. Thus, a new anti-hypertensive treatment, which acts on a broader patient population, would be an important addition to existing treatments. A number of vasoconstrictive agents, including angiotensin II, endothelin-1, and urotensin-II, exert their effect through RhoA and the downstream kinase Rho-kinase (ROCK1).1 Because of its central role in the control of smooth muscle contraction, inhibition of ROCK1 could lead to a more broadly efficacious anti-hypertensive agent.2 ROCK1 inhibitors have been shown to relax vascular smooth muscle and lower blood pressure in several animal models of hypertension.3 Therefore, we began an effort to identify potent ROCK1 inhibitors with pharmacokinetic profiles consistent with once daily oral dosing.